An interventional study of ImPACT in Pediatric Cancer and Cognitive Dysfunction, sponsored by Aarhus University Hospital. Completed at 1 site in Denmark. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Aarhus University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the present pilot study is to evaluate the feasibility, acceptability, and preliminary efficacy of a novel, context-sensitive neuropsychological rehabilitation intervention for childhood cancer survivors and their families.
Cognitive impairment is the most common late effect in childhood cancer survivors, and despite the negative effects of these symptoms on quality of life, scholastic achievement and long-term socioeconomic outcomes, there continues to be no "gold standard" treatment for childhood cancer survivors with cognitive impairment.
Indeed, there is a dearth of research on interventions to treat cognitive impairment in childhood cancer survivors, and the relatively few studied interventions have proven limited effects. Arguably, four key elements are missing from a majority of studied interventions:1) transfer of learning to real-world functional outcomes, 2) awareness training to enhance compensatory strategy use, 3) inclusion of parents that could enhance transfer of learning to the home, and 4) recognition of the inter-related nature of cognitive, neurobehavioral, and psychological functions.
The "I'M aware: Parents and Children Together (ImPACT)" program is a novel, context-sensitive neuropsychological rehabilitation intervention that targets the above mentioned missing elements in previous rehabilitation efforts. The present pilot study aims to assess the feasibility, acceptability, and preliminary efficacy of this program in childhood cancer survivors with cognitive impairment in preparation for a large-scale randomized controlled trial.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 10 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The ImPACT program consists of 8 weekly 1-hour sessions with homework between sessions.
Behavioral: ImPACT
During the ImPACT program, the childhood cancer survivor and at least one parent collaborates on: 1. Becoming aware of the child's core strengths and difficulties 2. Helping the child to be optimally responsive to the guidance of the parent(s), and 3. Creating compensatory strategies to respond to real-world manifestations of the child's difficulties and helping the child implement these strategies at home.
Parent-reported neurobehavioral functioning
The parent-report screening version of the Behavior Rating Inventory of Executive Function 2nd Edition (BRIEF-2). 12 items: answer format range: 1-3; total score range: 12-36. Higher score indicates more impairment.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Parent-reported cognitive functioning
The parent-report version of the Pediatric Perceived Cognitive Function (PedsPCF) Short Form. 7 items: answer format range 1-5; total score range: 7-35. Lower score indicates more impairment.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Parent-reported neurobehavioral functioning
The parent-report version of the Behavior Rating Inventory of Executive Function 2nd Edition (BRIEF-2). 63 items: answer format range: 1-3; total score range: 63-189. Higher score indicates more impairment.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Parent-reported cognitive functioning
The parent-report version of the Pediatric Perceived Cognitive Function (PedsPCF) Short Form. 7 items: answer format range 1-5; total score range: 7-35. Lower score indicates more impairment.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Child-reported neurobehavioral functioning
The child-report version of the Behavior Rating Inventory of Executive Function 2nd Edition (BRIEF-2). 55 items: answer format range: 1-3; total score range: 55-165. Higher score indicates more impairment.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Child-reported neurobehavioral functioning
The child-report version of the Behavior Rating Inventory of Executive Function 2nd Edition (BRIEF-2). 55 items: answer format range: 1-3; total score range: 55-165. Higher score indicates more impairment.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Child-reported cognitive functioning
The child-report version of the Pediatric Perceived Cognitive Function (PedsPCF) Short Form. 7 items: answer format range 1-5; total score range: 7-35. Lower score indicates more impairment.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Child-reported cognitive functioning
The child-report version of the Pediatric Perceived Cognitive Function (PedsPCF) Short Form. 7 items: answer format range 1-5; total score range: 7-35. Lower score indicates more impairment.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Parent-reported pediatric quality of life
The parent-report version of the Pediatric Quality of Life (PedsQL) Core and Cancer scale. 23 items for the Core Scale, 25 items for the Cancer Scale: answer format range: 0-4; total score range: 0-100 (both scales). Lower scores indicate more impairment.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Parent-reported pediatric quality of life
The parent-report version of the Pediatric Quality of Life Inventory (PedsQL) Core and Cancer scale. 23 items for the Core Scale, 25 items for the Cancer Scale: answer format range: 0-4; total score range: 0-100 (both scales). Lower scores indicate lower quality of life.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Child-reported pediatric quality of life
The child-report version of the Pediatric Quality of Life (PedsQL) Core and Cancer scale. 23 items for the Core Scale, 25 items for the Cancer Scale: answer format range: 0-4; total score range: 0-100 (both scales). Lower scores indicate more impairment.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Child-reported pediatric quality of life
The child-report version of the Pediatric Quality of Life (PedsQL) Core and Cancer scale. 23 items for the Core Scale, 25 items for the Cancer Scale: answer format range: 0-4; total score range: 0-100 (both scales). Lower scores indicate more impairment.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Parent-reported pediatric anxiety and depression
The parent-report version of the Revised Children's Anxiety and Depression Scale (CADS) Short Form. 47 items: answer format range: 0-3; total score range: 0-27 (social phobia and panic disorder subscales), 0-30 (major depressive disorder subscale), 0-21 (social anxiety disorder subscale), 0-18 (generalized anxiety disorder and obsessive compulsive disorder subscales). Higher scores indicate more anxiety and depression.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Parent-reported pediatric anxiety and depression
The parent-report version of the Revised Children's Anxiety and Depression Scale (CADS) Short Form. 47 items: answer format range: 0-3; total score range: 0-27 (social phobia and panic disorder subscales), 0-30 (major depressive disorder subscale), 0-21 (social anxiety disorder subscale), 0-18 (generalized anxiety disorder and obsessive compulsive disorder subscales). Higher scores indicate more anxiety and depression.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Child-reported pediatric anxiety and depression
The child-report version of the Revised Children's Anxiety and Depression Scale (CADS) Short Form. 47 items: answer format range: 0-3; total score range: 0-27 (social phobia and panic disorder subscales), 0-30 (major depressive disorder subscale), 0-21 (social anxiety disorder subscale), 0-18 (generalized anxiety disorder and obsessive compulsive disorder subscales). Higher scores indicate more anxiety and depression.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Child-reported pediatric anxiety and depression
The child-report version of the Revised Children's Anxiety and Depression Scale (CADS) Short Form. 47 items: answer format range: 0-3; total score range: 0-27 (social phobia and panic disorder subscales), 0-30 (major depressive disorder subscale), 0-21 (social anxiety disorder subscale), 0-18 (generalized anxiety disorder and obsessive compulsive disorder subscales). Higher scores indicate more anxiety and depression.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Parent-reported pediatric fatigue
The parent-report version of the Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS). 18 items: answer format range 0-4; total score range: 0-100. Lower score indicates more fatigue.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Parent-reported pediatric fatigue
The parent-report version of the Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS). 18 items: answer format range 0-4; total score range: 0-100. Lower score indicates more fatigue.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Child-reported pediatric fatigue
The child-report version of the Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS). 18 items: answer format range 0-4; total score range: 0-100. Lower score indicates more fatigue.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Child-reported pediatric fatigue
The child-report version of the Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS). 18 items: answer format range 0-4; total score range: 0-100. Lower score indicates more fatigue.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Parent sense of competence
The Parenting Sense of Competence Scale (PSC scale).17 items: answer format range 1-6; total score range: 16-102. Higher score indicates more competence.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Parent sense of competence
The Parenting Sense of Competence Scale (PSC scale). 17 items: answer format range 1-6; total score range: 16-102. Higher score indicates more competence.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Parent-reported participant motivation
The 7-item interest/enjoyment subscale of the Intrinsic Motivation Inventory (IMI). 7 items: answer format range 1-7; total score range: 1-7. Higher score indicates more motivation.
Time frame: After last session (approximately 9 weeks after Baseline assessment (T1): Post-intervention, T3)
Child-reported participant motivation
The 7-item interest/enjoyment subscale of the Intrinsic Motivation Inventory (IMI). 7 items: answer format range 1-7; total score range: 1-7. Higher score indicates more motivation.
Time frame: After last session (approximately 9 weeks after Baseline assessment (T1): Post-intervention, T3))
Parent-reported participant satisfaction
The Client Satisfaction Questionnaire (CSQ-8). 8 items: answer format range 1-4; total score range: 8-32. Higher score indicates better satisfaction.
Time frame: After last session (approximately 9 weeks after Baseline assessment (T1): Post-intervention, T3)
Child-reported participant satisfaction
The Client Satisfaction Questionnaire (CSQ-8). 8 items: answer format range 1-4; total score range: 8-32. Higher score indicates better satisfaction.
Time frame: After last session (approximately 9 weeks after Baseline assessment (T1): Post-intervention, T3)
Objective cognitive functioning (Child only)
Standard neuropsychological test battery. Different scoring formats.
Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)
Objective cognitive functioning (Child only)
Standard neuropsychological test battery. Different scoring formats.
Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)
Qualitative Interviews
Following the T4 assessment, the child and parent(s) will be invited to participate in a 30-minutes semi-structured, audio recorded interview.
Time frame: 9 week after post-intervention (approximately 18 weeks after Baseline assessment (T1): Follow-up, T4)
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Jun 2026, 44 months.
Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 44 months is above that.
Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2025 → Jun 2026 and completion Dec 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.